GET DAILY SIGNALSInvivyd (IVVD) Shares Decline -38% Over the Past Month After Key Updates
Key Takeaways
- Invivyd shares declined roughly 38% over the trailing 30 days, falling from a $0.95 close on September 28, 2026 to $0.5888 on October 27, 2026.
- The slide followed September 29 topline results from the LIBERTY Phase 3 study and a delay in the pivotal DECLARATION data readout to October.
- Over the trailing three months the stock is essentially flat, reflecting a sharp August-to-mid-September rally that fully reversed.
- Binary clinical catalysts, small-cap biotech volatility, and a leadership transition amplified the price swings.
- PEMGARDA net product revenue grew 21% year over year in Q2 2026, while the FDA has set a June 29, 2027 termination date for its emergency use authorization.
- For additional context, review Invivyd's Price Targets, Earnings, and Forecast pages for deeper data on valuation, results, and forward estimates.
- Traders monitoring momentum can also explore Trending AI Robots for automated strategies across a wide range of tickers.
Invivyd's Focus and Market Position
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on monoclonal antibody (mAb) therapies for serious viral infectious diseases, beginning with SARS-CoV-2. The company's proprietary INVYMAB platform combines viral surveillance and predictive modeling with advanced antibody engineering to generate antibodies designed to keep pace with viral evolution.
Invivyd's first authorized product, PEMGARDA (pemivibart), received emergency use authorization (EUA) from the U.S. Food and Drug Administration in March 2024 for the pre-exposure prophylaxis of COVID-19 in certain adults and adolescents who are immunocompromised. Its lead pipeline candidate, VYD2311, is being evaluated in the Phase 3 DECLARATION and LIBERTY studies as a next-generation COVID-19 prevention antibody. The company is also advancing earlier-stage candidates targeting measles (VMS063) and respiratory syncytial virus (VBY329). Investors follow IVVD closely for binary clinical readouts and regulatory milestones that can move the stock sharply in either direction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
IVVD Stock Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, IVVD fell approximately 38%, from a closing price of $0.95 on September 28, 2026 to $0.5888 on October 27, 2026. The decline was not a single-day event but a steady erosion that reversed a mid-September surge, when shares briefly traded above $1.00 around September 21 before rolling over.
The picture is different over the trailing quarter. From a close of about $0.59 in late July 2026 to roughly $0.59 in late October, the stock is essentially flat, down less than 1%. That three-month span included a sharp August-to-September advance driven by anticipation of VYD2311 data, followed by a full retracement after the mixed September 29 update. The divergence between the 30-day and quarterly figures underscores how much of the recent move reflects a reversal of prior gains rather than a wholly new leg lower.
What Drove the Recent 30-Day Move in IVVD
The primary catalyst was the September 29, 2026 update on VYD2311. Invivyd reported positive topline results from the LIBERTY Phase 3 study, showing VYD2311 offered safety and tolerability superior to an mRNA-based COVID-19 vaccine, with no adverse events exceeding Grade 2 severity, and improved vaccine-induced neutralizing titers by approximately 2.5-fold. However, the company also disclosed that topline safety and immunogenicity data from the pivotal DECLARATION study would now be reported in October, a delay from its earlier third-quarter guidance.
That mixed message triggered a double-digit single-day decline as traders reacted to the pushed-back timeline for the more consequential DECLARATION readout. The September data release also coincided with a leadership transition announced earlier in the month, when Marc Elia stepped into the chief executive officer role alongside a strategic reassessment of the DECLARATION study. Small-cap biotech names with binary catalysts tend to experience outsized volatility, and IVVD's slide extended through October as momentum faded and profit-taking continued. Despite the pullback, analysts at BTIG and H.C. Wainwright reiterated Buy ratings with $10.00 price targets in late September.
The Broader Three-Month Context for IVVD
The broader three-month narrative centered on VYD2311. Through August and the first half of September, IVVD rallied from the mid-$0.50s toward $1.00 as investors positioned ahead of pivotal data and regulatory clarity. Supporting sentiment was continued commercial execution: PEMGARDA net product revenue reached $14.3 million in Q2 2026, up 21% year over year, while cash and equivalents stood at $160.1 million as of June 30, 2026, expected to fund the company through the DECLARATION readout and support launch readiness.
That optimism was tempered by regulatory uncertainty. In July, Invivyd disclosed that the FDA had notified the company that PEMGARDA's EUA is scheduled to terminate on June 29, 2027, following the planned end of the federal COVID-19 emergency use declaration. The prospect of transitioning from an EUA to a potential Biologics License Application for VYD2311, and the sequencing of the DECLARATION data, kept the stock range-bound on net even as it experienced sharp intra-quarter swings.
Key Catalysts Ahead for IVVD Investors
The most important near-term catalyst is the pending topline data from the DECLARATION Phase 3 trial, which Invivyd has indicated would be reported in October. The readout will inform the company's regulatory strategy for VYD2311, including whether it pursues accelerated approval based on antiviral activity and safety or a conventional Biologics License Application. Investors will also monitor the FDA transition process for PEMGARDA ahead of its scheduled June 29, 2027 EUA termination, and any updates on the company's cash runway and quarterly revenue trends. Pipeline progress for VMS063 and VBY329, macroeconomic and sector conditions affecting small-cap biotech, and analyst rating changes remain additional factors worth following. As with all clinical-stage companies, outcomes are uncertain, and investors should weigh these catalysts against the inherent risks of binary trial events. From what I see, this is important because the timing of these events can shift sentiment quickly.
Using AI Tools in My Research Process
In my own work, I often turn to Tickeron's AI tools to help spot patterns and compare opportunities across biotech names like IVVD. One resource that stands out is the Trending AI Robots page, which highlights a curated selection of AI-powered trading bots drawn from a broader ecosystem of hundreds of bots that trade thousands of tickers. Only top-performing and most relevant strategies appear in this section, which is designed to help traders and investors identify automated approaches that are currently standing out. The bots vary widely in strategy, holding timeframe, and performance metrics, allowing users to compare options based on their own objectives and risk tolerance. For those interested in data-driven, systematic approaches to the market, this page offers a practical starting point for further exploration.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IVVD's RSI Indicator ascends from oversold territory
The RSI Indicator for IVVD moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In 43 of the 46 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVVD advanced for three days, in 186 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVVD as a result. In 65 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for IVVD turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 35 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
IVVD moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IVVD crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVVD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVVD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.958) is normal, around the industry mean (2.974). P/E Ratio (-1.899) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (3.722) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. IVVD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVVD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement